Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma — ESCC-307PLAH

Esophageal Squamous Carcinoma Clinical Trial

Official title:
A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to test the safety and effectiveness of erlotinib and chemoradiotherapy in patients with unresectable esophageal or gastro-esophageal squamous cancer .

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01752205
Study type	Interventional
Source	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Contact	Xu jianming, M.D.
Phone	861051128358
Email	jmxu2003@yahoo.com
Status	Recruiting
Phase	Phase 3
Start date	November 2012
Completion date	November 2014

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT06055153` - DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC	Phase 1/Phase 2
	Recruiting	`NCT05164848` - JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy	Phase 1